"","Num","POD","SD","%","Genes","KE"
"PANCREATIC HYPOPLASIA","2","0.00508852708261543","1.24331187294415","28.57","hnf1ba, pdx1","INCREASED PANCREATIC ACINAR TUMORS"
"ABNORMAL BLOOD POTASSIUM CONCENTRATION","2","0.0139561178428841","1.57128904862657","16.67","gatm, nr3c2","INCREASED BLOOD POTASSIUM CONCENTRATION"
"GO:0004666","3","0.0418803684299001","0.863884852600784","75","ptgs1, ptgs2a, ptgs2b","INHIBITION CYCLOOXYGENASE ACTIVITY; INHIBITION CYCLOOXYGENASE 1 ACTIVITY"
"GO:0015631","3","0.0499492392697021","0.755779759447085","15.79","hdac6, rae1, tprb","BINDING TUBULIN"
"NEURODEGENERATION","4","0.0736440297637233","0.498077701407421","26.67","dlat, fus, hnrnpa1b, rnaseh2b","N/A NEURODEGENERATION"
"GO:0004738","3","0.0741349011948379","0.851241263617153","75","dlat, pdhb, pdhx","INCREASED INDUCTION OF PYRUVATE DEHYDROGENASE PDH; INHIBITION PYRUVATE DEHYDROGENASE KINASE PDK ENZYME"
"CELLULAR SODIUM ION HOMEOSTASIS","3","0.0741892931829554","0.840081590765647","60","agtr2, atp1b3b, slc8a1a","INHIBITION NA+/I- SYMPORTER NIS"
"HYPERACTIVITY","10","0.0793073735165341","0.210113266641989","20","adsl, agtr2, cars, dyrk1ab, fgfr1b, gamt, glud1a, msh6, ppp2r1b, thrb","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION","3","0.0854027582137868","0.820735558540453","30","dyrk1ab, hdac6, rac1a","DEPOLYMERIZATION MICROTUBULE"
"GO:1903008","3","0.0856309173044132","0.821014984268844","23.08","hdac6, park7, pelo","DISRUPTION LYSOSOME"
"GO:0048813","5","0.103065505178708","0.339006945235495","38.46","cdc42, gsk3b, hdac6, id1, ilk","ABERRANT DENDRITIC MORPHOLOGY"
"GO:0006915","4","0.114791086962138","0.532066565896884","12.9","casp3b, casp9, caspb, dap3","CHANGES/INHIBITION CELLULAR HOMEOSTASIS AND APOPTOSIS; DECREASED APOPTOSIS EPITHELIAL CELLS; INCREASED APOPTOSIS DECREASED LEYDIG CELLS"
"GO:0001516","4","0.115195657038115","0.572830783655751","100","ptgesl, ptgs1, ptgs2a, ptgs2b","REDUCED PROSTAGLANDIN F2ALPHA SYNTHESIS OVARY; DECREASED PROSTAGLANDIN F2ALPHA SYNTHESIS OVARY"
"GO:1903409","7","0.11898607774948","0.294994691310842","28","agtr2, mmp13a, park7, ptgs2b, rac1a, roraa, slc18a2","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"GO:0007588","4","0.119008405515765","0.525782940383605","28.57","agtr2, avpr1a, drd2b, hmox1a","INCREASE BILIARY EXCRETION TH GLUCURONIDE"
"GO:0046879","4","0.143290941213367","0.537235956420709","33.33","CCKAR, hnf1ba, park7, trh","DECREASED GNRH PULSATILITY/RELEASE IN HYPOTHALAMUS; DECREASED LH SURGE FROM ANTERIOR PITUITARY; INCREASED SECRETION OF GNRH FROM HYPOTHALAMUS; DECREASED GNRH PULSATILITY/RELEASE IN HYPOTHALAMUS; DECREASED LH SURGE FROM ANTERIOR PITUITARY"
"LIPID ACCUMULATION IN HEPATOCYTES","9","0.145940737913429","0.200683077903189","28.12","atp6ap1b, cpt1aa, farsb, hnf1ba, hnrnpa1b, iars, ldlra, lipf, pmm2","INCREASE PRENEOPLASTIC FOCI HEPATOCYTES"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","14","0.149984497095598","0.129447506639957","13.73","arntl1b, bmp4, esrra, esrrga, foxa1, hdac1, hdac6, nr3c2, paqr7b, park7, pparab, rxraa, src, taf7","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"GO:0016209","4","0.158976420127531","0.592312620325822","36.36","cat, park7, ptgs1, ptgs2b","OXIDATION GLUTATHIONE"
"GO:0006636","5","0.163536294097984","0.410664378548268","41.67","avpr1a, ptgesl, ptgs1, ptgs2b, tbxas1","UP REGULATION UNSATURATED FATTY ACID"
"ABNORMAL BLOOD SODIUM CONCENTRATION","4","0.165853939757143","0.549532634293581","44.44","cpox, fgfr1b, nfkb2, nr3c2","DECREASED SODIUM CONDUCTANCE 2; DECREASED SODIUM REABSORPTION"
"GO:0046562","4","0.174111448305603","0.553281669342493","14.81","adh5, aldh9a1a.1, dlat, pdhb","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"GO:0007269","5","0.19251238933997","0.35472871559832","20","drd2b, gsk3b, rab5ab, rap1aa, slc18a2","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"GO:0050663","6","0.198053270643468","0.276497786334555","20","agtr2, drd2b, mmp13a, nr1h4, src, xbp1","RELEASE CYTOKINE"
"GO:0015908","5","0.207921932354789","0.380060670740974","22.73","agtr2, cpt1aa, drd2b, pparab, rps6kb1b","INCREASED FA INFLUX"
"PROSTAGLANDIN SYNTHESIS AND REGULATION","6","0.237829426784748","0.312989958348679","23.08","ednraa, ptger2a, ptger2b, ptgs1, ptgs2b, tbxas1","REDUCTION PROSTAGLANDIN E2 CONCENTRATION; REDUCED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"GO:0003707","13","0.239635215870244","0.125550335851969","40.62","esrra, esrrga, nr1h3, nr1h4, nr2f6a, nr3c2, paqr7b, pparab, rarga, roraa, rxraa, thraa, thrb","REDUCED MATURATION INDUCING STEROID RECEPTOR SIGNALLING OOCYTE"
"CHOLESTASIS","12","0.268394663249079","0.135368593925581","34.29","alg8, atp6ap1b, cpox, farsb, fh, hnf1ba, iars, krt8, lipf, nr1h4, rnaseh2b, trhra","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"ABNORMALITY OF THE BLADDER","12","0.291586977761494","0.144339382302582","23.08","agtr2, cdk6, fus, glud1a, hnrnpa1b, hs6st2, hspa9, nfia, pax6b, rarga, sdhb, smo","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","5","0.292466988658472","0.396182638827228","5.43","lipf, nfkb2, nr3c2, smo, sox19b","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"OXIDATIVE STRESS","3","0.3057749290321","0.496715686348948","12.5","cat, hmox1a, mt2","PROPAGATION OXIDATIVE STRESS; N/A OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASED OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASE ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS; INCREASED ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS"
"GO:0019932","14","0.316879353795478","0.109381047461991","22.95","adra2c, agtr2, ahr1b, avpr1a, crhr1, drd2b, gsk3b, npy2r, oprl1, pdx1, ppp2ca, ppp2r1b, ptger2a, ptger2b","INCREASED SECOND MESSENGER PRODUCTION"
"NUCLEAR RECEPTORS","8","0.317455160063303","0.199541680203911","15.38","esrra, nr1h3, pparab, rarga, roraa, rxraa, thraa, thrb","ACTIVATION HEPATIC NUCLEAR RECEPTORS"
"GO:0003824","8","0.35515929517246","0.195263126815687","12.31","adsl, atic, fh, mdh1aa, mthfd1b, naga, pdhb, ppm1bb","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"UPPER MOTOR NEURON DYSFUNCTION","38","0.360294253275635","0.041644440048678","8.02","adsl, agtr2, bckdha, cars, cpt1aa, cyb5a, dlat, dyrk1ab, eif2b2, eif2b4, fgfr1b, fus, gabbr2, gamt, gria3b, hnrnpa1b, iars, mdh1aa, mre11a, msh6, naga, ndufa12, ndufs2, ndufs8a, nup107, nup133, ogdhb, park7, pax6b, pccb, pdhx, polr1c, rnaseh1, rnaseh2b, roraa, sdhb, slc18a2, smo","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"GO:0001525","11","0.375202289483327","0.125595373159793","29.73","flt1, gsk3b, hdac3, hdac6, hs6st2, mt2, nfkb2, rab5c, rps29, vegfaa, wdr43","REDUCTION ANGIOGENESIS; INCREASED ANGIOGENESIS"
"RENAL TUBULAR DYSFUNCTION","7","0.392204366820372","0.234405683214942","26.92","cpt1aa, gatm, hnf1ba, ndufs2, ndufs8a, pdx1, pmm2","INCREASE HYPERPLASIA RENAL TUBULAR CELLS; INCREASE CYTOTOXICITY RENAL TUBULAR CELL; INCREASE ADENOMAS/CARCINOMAS RENAL TUBULAR; OCCURRENCE RENAL PROXIMAL TUBULAR NECROSIS"
"GO:0043542","7","0.412826166573562","0.23302762939033","20","agtr2, bmp4, EPHA2_2of2, fgfr1b, hmox1a, id1, ptgs2b","INCREASED MIGRATION ENDOTHELIAL CELLS"
"GO:0030545","6","0.428913933990506","0.299818532112396","10.17","agtr2, bmp4, inhbaa, tgfb2, tgfb3, trh","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"GLOMERULAR SCLEROSIS","6","0.43599446781389","0.281277572446192","42.86","fh, nup107, nup133, nup93, sdhb, sec61a1","DECREASED GLOMERULAR FILTRATION"
"LOCOMOTORY BEHAVIOR","7","0.446687462939805","0.222312768920379","11.29","arrb2b, egr1, foxa2, ncoa2, npy2rl, park7, slc18a2","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"ABNORMAL FORM OF THE VERTEBRAL BODIES","10","0.447505096289847","0.132355804466335","30.3","fgfr1b, fzd2, hdac6, hspa9, kdelr2b, lfng, plod3, pmm2, rps19, tbxas1","CLONAL EXPANSION/CELL PROLIFERATION TO FORM ALTERED HEPATIC FOCI AHF"
"GO:0044414","11","0.465670913630428","0.109897787162701","27.5","actb1, atp6ap1b, colec11, ctsla, rab5ab, rab5c, rac1a, sec61a1, sec61al2, tuba8l, TUBB8P7_2of3","SUPPRESSION IMMUNE SYSTEM"
"ABNORMAL NASAL MORPHOLOGY","40","0.468360565227448","0.0339532595815941","25.81","actb1, adsl, agtr2, ahr1b, aldh6a1, atic, cars, cdc42, colec11, dyrk1ab, ednraa, fgfr1b, fh, fzd2, hdac6, hspa9, kif1bp, lfng, map2k2a, mdh1aa, naga, nfia, nkx2.7, nras, orc6, plod3, pmm2, polr1c, ppp2r1b, prpf31, prpf4, rac1a, rarga, rbm8a, rpl18, rps19, rps23, rps29, smo, strada","INCREASE SITE OF CONTACT NASAL TUMORS"
"GO:0046903","54","0.471353189964029","0.0270863845199774","23.38","actn1, adra2c, agtr2, atp6ap1b, avpr1a, cat, CCKAR, cpt1aa, crhr1, drd2b, fgfr1b, foxa2, glud1a, gsk3b, hmox1a, hnf1ba, inhbaa, llgl2, mmp13a, myb, ncoa1, npy2r, nr1h3, nr1h4, nras, oprl1, park7, pdx1, ppat, psma5, psmc2, psmd1, psmd13, psmd14, psmd6, ptgesl, ptprb, rab5ab, rab5c, rac1a, rap1aa, rock1, slc18a2, slc25a5, SLC29A1_1of2, src, stxbp2, tcf7l2, tgfb2, tgfb3, timp2a, trh, wls, xbp1","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"GO:0006412","24","0.474948375873368","0.0627221832705198","22.22","eif2b2, eif2b4, eif2s1b, eif2s2, eif3d, eif3ha, eif3i, eif3ja, eif4bb, faua, gspt1l, iars, rpl14, rpl18, rpl18a, rpl21, rpl4, rps17, rps19, rps23, rps29, rps3a, rps9, uba52","ALTERED PROTEIN PRODUCTION"
"GO:0006936","10","0.483550019742174","0.130961472065439","18.18","adra2c, atp2a1, drd2b, ednraa, gamt, npy2r, ptgs2b, rock1, rps6kb1b, tpm4a","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"VASCULAR CALCIFICATION","2","0.484137711198305","0.102816657219459","40","ldlra, rnaseh2b","OSTEOPOROSIS AND VASCULAR CALCIFICATION BONE DETERIORATION"
"RESPONSE TO REACTIVE OXYGEN SPECIES","13","0.510338276566051","0.100382344917943","23.21","casp3b, cat, hdac1, hdac6, hmox1a, hsf1, jun, mt2, myb, park7, pdgfra, slc8a1a, src","INCREASED REACTIVE OXYGEN SPECIES"
"GO:0006633","9","0.5112743653142","0.17409796996088","31.03","avpr1a, cyp3c1, hacd3, nr1h3, ptgesl, ptgs1, ptgs2b, tbxas1, xbp1","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"OXIDATIVE DAMAGE","3","0.514437830145396","0.196680155264053","15","casp3b, casp9, cdc42","INCREASED OXIDATIVE DAMAGE"
"ABNORMAL LIVER MORPHOLOGY","27","0.527384794834364","0.0514953858521","22.69","alg8, atp6ap1b, cox5aa, cpox, cpt1aa, farsb, flt1, hmox1a, hnf1ba, hnrnpa1b, iars, krt8, ldlra, lipf, naga, ndufs2, ndufs8a, nhp2, nr1h4, nras, pccb, pdgfra, pmm2, rbm8a, rnaseh2b, rras, stxbp2","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"GO:0099536","20","0.532800109815586","0.0700155842893341","18.02","agrn, arrb2b, drd2b, gabbr2, gabra6b, gria1b, gria3b, gsk3b, npy2r, park7, pcdh17, plat, ptgs2b, rab5ab, rap1aa, slc18a2, SLC29A1_1of2, src, usp14, vdac3","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"GO:0060291","2","0.582028231911746","0.0841412528786994","14.29","drd2b, gsk3b","DECREASED LONG-TERM POTENTIATION LTP"
"MORTALITY AGING","8","0.630959091864716","0.187524558512131","30.77","cox5aa, hdac6, lipf, msh6, nras, ogdhb, rbm8a, smo","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"GO:0004872","57","0.632425050734679","0.0204212725189086","23.85","adra2c, agtr2, arrb2b, avpr1a, avpr1b, bmp4, CCKAR, crhr1, drd2b, ednraa, EPHA2_2of2, esrra, esrrga, fgfr1b, flt1, fzd2, gabbr1b, gabbr2, gabra6b, gnrhr1, gria1a, gria1b, gria3b, grm1b, inhbaa, mtnr1c, npy2r, npy2rl, nr1h3, nr1h4, nr2f5, nr2f6a, nr3c2, opn1sw2, opn4a, oprl1, paqr3a, paqr7b, pdgfra, pparaa, pparab, ptger2a, ptger2b, rarga, roraa, rorab, rxraa, smo, tgfb2, tgfb3, thraa, thrb, trh, trhra, trhrb, valopa, vegfaa","ACTIVATION PXR/SXR"
"DECREASED BODY WEIGHT","43","0.66349874078717","0.0299561909343615","19.03","actb1, agtr2, ak2, alg8, birc2, bmp4, cars, cox5aa, cyb5a, dyrk1ab, farsb, fgfr1b, fh, flt1, fus, gatm, gria3b, iars, lipf, map2k2a, msh6, ndufa12, ndufs2, ndufs8a, nfkb2, nr1h4, nr3c2, orc6, pccb, pdhb, pdhx, pdx1, pmm2, polr1c, pomp, rarga, rpl18, rps19, rps29, sdhb, strada, tgfb3, thrb","DECREASED BODY WEIGHT"
"ABNORMALITY OF THE LIVER","34","0.665991544782334","0.0370153567611618","4.53","alg8, atp6ap1b, cox5aa, cpox, cpt1aa, farsb, fh, flt1, hmox1a, hnf1ba, hnrnpa1b, iars, krt8, ldlra, lipf, msh6, myca, naga, ndufs2, ndufs8a, nfkb2, nhp2, nr1h4, nras, pccb, pdgfra, pdx1, pmm2, rbm8a, rnaseh2b, rras, sdhb, stxbp2, trhra","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"GO:0006629","44","0.666264635041417","0.028717268421246","21.36","adh5, agrn, alg8, avpr1a, bdh2, cat, cdc42, cpt1aa, crls1, csnk1g2a, cyp3c1, dbi, egr1, fgfr1b, flt1, hacd3, hdac3, ivd, ldlra, lipf, naga, ncoa1, ncoa2, nr1h3, nr1h4, pccb, pdgfra, pgp, pparab, ppp2ca, ppp2r1b, ptgesl, ptgs1, ptgs2b, rab5ab, rdh10a, roraa, rxraa, sirt2, src, tbxas1, thraa, xbp1, zgc-86598","ALTERATION LIPID METABOLISM"
"FARNESOID X RECEPTOR PATHWAY","3","0.675946199913957","0.144491185163874","30","cyp3c1, nr1h4, rxraa","ACTIVATION NR1H4"
"GO:0006954","23","0.678401315095396","0.0562160070761621","19.66","agtr2, birc2, EPHA2_2of2, f11r.1, hmox1a, jun, ldlra, lipf, mmp13a, nfkb2, nr1h3, nr1h4, park7, pparab, ptger2a, ptger2b, ptgs1, ptgs2b, rac1a, roraa, rps19, seh1l, smo","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"ABNORMALITY OF THE ABDOMINAL ORGANS","38","0.696454211138858","0.0315433328710152","22.49","alg8, atp6ap1b, bckdha, cox5aa, cpox, cpt1aa, farsb, fh, flt1, hmox1a, hnf1ba, hnrnpa1b, iars, krt8, ldlra, lipf, mre11a, msh6, myca, naga, ndufs2, ndufs8a, nfkb2, nhp2, nr1h4, nras, pccb, pdgfra, pdx1, pmm2, rarga, rbm8a, rnaseh2b, rras, sdhb, stxbp2, tbxas1, trhra","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"GO:0045333","20","0.72796866820239","0.067380038428684","27.78","adsl, cat, ccnb1, cox5aa, COX5B_2of3, cox6b1, cox7c, cs, cyc1, dlat, fh, mdh1aa, ndufa12, ndufa5, ndufa8, ndufs2, ndufs8a, park7, pdhb, sdhb","INCREASE OXIDATIVE METABOLISM"
"GO:0005488","270","0.73029937697797","0.00418463479962563","25.09","actb1, actn1, adh5, adra2c, adssl, agrn, ahr1b, ak2, AK6, ap2b1, ap2m1a, arntl1b, arntl2, arrb2b, atf6, atp2a1, atp5g3a, atp5g3b, avpr1a, avpr1b, bambia, bambib, birc2, bmp4, brk1, cars, caspb, cat, cdc42, cdc5l, cdk6, colec11, cpsf5, crhr1, csnk1e, csnk1g2a, CSNK2A1, cstf3, ctps1a, cul1a, cyb5a, cyc1, cyp2aa3, cyp2ad2, cyp2ad3, cyp2p6, cyp3c1, dao.1, dbi, dyrk1ab, E2F1, egr1, eif2b2, eif2b4, eif2s1b, eif2s2, eif3d, eif3ha, eif3i, eif3ja, eif4bb, elavl1, EPHA2_2of2, esrra, esrrga, ewsr1b, f11r.1, fabp10a, farsb, fgfr1b, flt1, foxa1, foxa2, foxk2, foxo1a, fus, fzd2, gnb1b, gng12a, gnl3, gnrhr1, gpd1c, gsk3b, GSK3B_2of2, gspt1l, gtf2b, gtf2h4, h2afx, hdac1, hdac3, hdac6, hmox1a, hnf1ba, hnrnpa1b, hsf1, hsp90b1, hspa9, iars, id1, igfbp2b, igfbp6b, ilk, imp4, inhbaa, ivd, jun, kdelr2b, ldlra, lfng, lhx2b, llgl2, lman2, lsm1, map2k2a, MAP3K14_2of2, mapk12a, mcl1a, mitfa, mmp13a, mmp16b, mmp17b, mre11a, msh6, mt2, mthfd1b, myb, myca, ncoa1, ncoa2, ndufs2, ndufs8a, nfia, nfkb2, nhp2, nkx2.7, nme3, nol6, nploc4, npy2r, npy2rl, nr1h3, nr1h4, nr2f5, nr2f6a, nr3c2, nras, nsfl1c, nvl, ogdhb, onecut1, oprl1, orc6, otpb, oxsr1a, p4ha2, pak2a, paqr7b, park7, pax6b, pcdh17, pdgfra, pdx1, pelo, pgd, plod3, pole4, polr1c, polr1e, polr2j, polr3k, pparaa, pparab, ppat, ppm1bb, ppp1caa, prpf31, prpf4, psmc1a, psmc1b, psmc2, psmc4, psmc6, psmd14, ptgesl, ptgs1, ptgs2a, ptgs2b, ptprb, pvalb2, rab5ab, rab5c, rac1a, rae1, rap1aa, rarga, rbm17, rbm8a, rchy1, rhoaa, riok1, riok2, rnaseh1, rnf185, rnf2, rock1, roraa, rorab, rpa1, rpa3, rpl14, rpl18, rpl4, rps19, rps29, rps6kb1b, rps9, rras, rrp7a, rtn4a, rxraa, sae1, sdhb, sec61a1, sec61al2, setdb1b, sf3a2, sf3b3, sf3b6, sirt2, smarcb1b, smndc1, smo, smx5, snrpa, snrpd3l, snrpe, sox19b, sqrdl, src, srp9, srsf3b, srsf5b, strada, stxbp2, tbxas1, tcf7l1b, tcf7l2, tgfb2, tgfb3, thop1, thraa, thrb, timp2a, tph1b, tpm4a, trh, TUBB8P7_2of3, u2af1, uba2, uba3, uba52, ube2kb, ube2nb, usf1, usf1l, vegfaa, wdr3, wls, xbp1, zgc-86598","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"GO:0045444","9","0.732971437921738","0.15747358160506","21.95","aldh6a1, E2F1, hdac6, ptgs2b, roraa, sirt2, tcf7l2, tph1b, xbp1","INCREASED ADIPOGENESIS"
"PEPTIDYL LYSINE MODIFICATION","23","0.743515716576863","0.0392436416750183","32.39","egr1, gnl3, gtf2b, hdac1, hdac6, myb, ncoa1, ndc1, nup107, nup133, nup93, park7, plod3, pwp1, rae1, sae1, seh1l, setdb1b, sirt2, taf10, taf7, tprb, uba2","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0005102","43","0.746827389378593","0.0266804685649294","20.67","actn1, adra2c, agtr2, ap2m1a, arrb2b, avpr1a, bambia, bmp4, casp3b, cat, ccnb1, cdc42, dbi, drd2b, f11r.1, fgfr1b, fus, gtf2b, hsp90b1, igfbp6b, ilk, inhbaa, ncoa1, ncoa2, nr1h4, park7, pdgfra, plat, ppp2ca, rarga, rxraa, smo, src, strap, taf10, taf7, tcf7l2, tgfb2, tgfb3, timp2a, trh, uba3, wls","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"GO:0019904","30","0.751430102510151","0.0424618446604536","24.39","arrb2b, casp9, cdc42, cdc5l, esrra, esrrga, f11r.1, fgfr1b, foxa1, foxa2, fzd2, gng12a, gria1b, hdac1, hnrnpa1b, ilk, jun, llgl2, map2k2a, mcl1a, ncoa2, pax6b, polr2j, pparab, rnf2, rps6kb1b, rxraa, src, tcf7l2, thraa","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"PYRUVATE METABOLIC PROCESS","13","0.762674946282693","0.0931964240078202","23.21","dlat, ndc1, nup107, nup133, nup93, ogdhb, pdhb, pdhx, pparab, rae1, sec13, seh1l, tprb","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"HEART DEVELOPMENT","22","0.797743886454662","0.0463186585143238","17.46","agtr2, ap2b1, arrb2b, bmp4, casp3b, ccnb1, cdc42, ednraa, foxa2, fzd2, mthfd1b, nkx2.7, npy2rl, pdgfra, pparab, rarga, rock1, rtn4a, slc8a1a, smo, tgfb2, vegfaa","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"CYANOSIS","3","0.800442407181771","0.143615524957643","15.79","agrn, cyb5a, rnaseh2b","N/A CYANOSIS OCCURS"
"ABNORMALITY OF THE MITOCHONDRION","10","0.809202336713176","0.140092586379727","7.94","ak2, cox5aa, dlat, fus, gatm, ndufa12, ndufs2, ndufs8a, pdhb, pdhx","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"GO:0035357","2","0.822495665647478","0.279400158406391","66.67","actn1, rxraa","ACTIVATION LXR ALPHA; DECREASED PPAR-ALPHA ACTIVATION; DECREASED PPAR-BETA ACTIVATION; DECREASED PPAR-GAMMA ACTIVATION; INHIBITION PPAR ALPHA; ACTIVATION OF SPECIFIC NUCLEAR RECEPTORS PPAR-GAMMA ACTIVATION; INCREASED PPAR-ALPHA ACTIVATION"
"CYTOPLASMIC RIBOSOMAL PROTEINS","14","0.830632651235088","0.0905727234509816","9.72","rpl14, rpl18, rpl18a, rpl21, rpl4, rplp2l, rps19, rps23, rps25, rps29, rps3a, rps6kb1b, rps9, uba52","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"REGULATION OF WNT SIGNALING PATHWAY","26","0.830646983290484","0.035513639983345","32.91","arntl1b, bambia, csnk1e, csnk1g2a, egr1, gsk3b, hdac1, igfbp6b, ilk, ppp2r1b, psma5, psmb3, psmc1b, psmc2, psmc4, psmc6, psmd1, psmd10, psmd13, psmd14, psmd5, psmd6, psme3, src, tcf7l2, wls","INHIBITION WNT PATHWAY"
"GO:0003714","5","0.831135183024072","0.0791918456644358","25","hdac1, hdac3, nr1h4, sap18, thrb","STABILIZATION PPAR ALPHA CO-REPRESSOR"
"GO:0046983","54","0.837484399987235","0.019090365943683","27.41","actn1, adh5, adra2c, ahr1b, arntl2, atf6, atic, atp2a1, cars, cat, cpox, cpsf5, dbi, drd2b, E2F1, elavl1, f11r.1, fgfr1b, gabbr2, gstm, h2afx, hmox1a, hnf1ba, hsf1, id1, inhbaa, jun, mcl1a, naga, ncoa1, ncoa2, nudt5, park7, pdgfra, pdx1, pole4, polr1c, polr2j, ppp2ca, ppp2r1b, ptgs2b, rchy1, rps19, rxraa, sae1, taf7, tgfb2, tgfb3, tpm4a, tprb, uba2, uba3, usf1, xbp1","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"GO:0010468","5","0.868264085694488","0.0797081870660609","31.25","arntl1b, lhx2b, mapk12a, pax6b, roraa","DECREASED TRANSCRIPTION OF GENES BY AR"
"GO:0005515","11","0.873625032529312","0.0397493887969804","23.4","arntl1b, arntl2, cdc42, fgfr1b, gnb1b, myb, rab5c, rtn4a, thraa, thrb, vegfaa","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"FAS LIGAND FASL PATHWAY AND STRESS INDUCTION OF HEAT SHOCK PROTEINS HSP REGULATION","5","0.88481361724842","0.0691069853620807","19.23","actb1, casp3b, casp9, jun, pak2a","ACTIVATION FAS; UP REGULATION FAS"
"CELL MIGRATION AND INVASION THROUGH P75NTR","3","0.897367750237346","0.125872845109122","16.67","jun, mmp13a, rac1a","INCREASED INVASION"
"REGULATION OF PROTEOLYSIS","29","0.90263095766684","0.0312910478953964","25.89","arrb2b, birc2, casp9, csnk1e, gsk3b, hdac1, hdac6, hsf1, mt2, myca, nr1h3, pak2a, park7, plat, psmc1b, psmc2, psmc4, psmd10, psmd14, psme3, rchy1, rnf185, rock1, sirt2, src, timp2a, ube2kb, usp14, vegfaa","IMPAIRED PROTEOSTASIS"
"ABNORMAL THYROID HORMONE LEVEL","3","0.916638045548631","0.159654779364059","15","thraa, thrb, trhra","INCREASED HEPATIC THYROID HORMONE UPTAKE/TRANSPORT; DECREASE SERUM THYROID HORMONE T4/T3; DECREASED THYROXINE T4 IN SERUM; DECREASED THYROXINE T4 IN TISSUES; DECREASED TRIIODOTHYRONINE T3 IN TISSUES; INCREASED TRIIODOTHYRONINE T3 IN TISSUES"
"GO:0050673","20","0.918639499736505","0.050132563165012","24.39","bmp4, cdc42, cdk6, EPHA2_2of2, fgfr1b, flt1, hmox1a, hnf1ba, id1, jun, krt8, map2k2a, nras, pax6b, rtn4a, smo, strap, tcf7l2, tgfb2, xbp1","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GO:0040011","40","0.92560653479446","0.0241899935797604","17.62","actn1, agrn, agtr2, arrb2b, bambia, bmp4, brk1, CCKAR, cdc42, cdk6, drd2b, EPHA2_2of2, f11r.1, fgfr1b, flt1, hdac6, hmox1a, id1, ilk, jun, krt8, lhx2b, map2k2a, onecut1, pax6b, pdgfra, plat, ptgs2b, rac1a, rock1, rps19, rps6kb1b, rras, rtn4a, smo, src, strap, tgfb2, usp14, xbp1","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"GO:0048870","37","0.925970746972344","0.0271011617656572","18.5","actn1, agtr2, arrb2b, bambia, bmp4, brk1, CCKAR, cdc42, cdk6, drd2b, EPHA2_2of2, f11r.1, fgfr1b, flt1, hdac6, hmox1a, id1, ilk, jun, krt8, map2k2a, onecut1, pax6b, pdgfra, plat, ptgs2b, rac1a, rock1, rps19, rps6kb1b, rras, rtn4a, smo, src, strap, tgfb2, xbp1","INCREASED MOTILITY"
"BILE ACID AND BILE SALT TRANSPORT","4","0.940933687475767","0.113719893617692","80","ncoa1, ncoa2, nr1h4, rxraa","INHIBITION BILE SALT EXPORT PUMP ABCB11"
"CTOME BILE ACID AND BILE SALT METABOLISM","4","0.940933687475767","0.113719893617692","80","ncoa1, ncoa2, nr1h4, rxraa","BILE ACCUMULATION PATHOLOGICAL CONDITION"
"GO:0016310","26","0.949715559668116","0.0376721301006837","20.8","ak2, AK6, cdk6, csnk1e, csnk1g2a, CSNK2A1, dyrk1ab, EPHA2_2of2, fgfr1b, flt1, gsk3b, GSK3B_2of2, ilk, map2k2a, mapk12a, nme3, pak2a, pdgfra, riok1, riok2, rock1, rps6kb1b, src, strada, strap, zgc-86598","ACTIVATION SP1"
"GO:0009790","47","0.951416774305437","0.0190961176916523","27.81","bmp4, brk1, casp3b, ccnb1, dad1, ednraa, eif2s2, EPHA2_2of2, fgfr1b, flt1, foxa1, foxa2, fzd2, hdac1, hnf1ba, hsf1, inhbaa, kif1bp, krt8, lfng, lhx2b, mmp13a, mmp16b, mthfd1b, ncoa1, nkx2.7, nmt1a, nup133, pax6b, pdgfra, pdx1, pelo, plod3, psmc4, rarga, rdh10a, rnaseh2b, rnf2, rock1, rrp7a, rtn4a, rxraa, sf3b6, smo, tgfb2, tgfb3, wls","DEFECT OF EMBRYOGENESIS"
"DRUG INDUCTION OF BILE ACID PATHWAY","2","0.965755375000279","0.240692920918966","16.67","cyp3c1, nr1h4","DECREASED BILE FLOW"
"GLUCOCORTICOID RECEPTOR PATHWAY","5","0.984192638664504","0.0841419524239878","20.83","birc2, jun, nfkb2, ptgs2b, rxraa","ACTIVATION GLUCOCORTICOID RECEPTOR"
"REGULATION OF CELL DEATH","61","1.00322780415374","0.014419918193552","22.76","actn1, agtr2, ap2b1, arrb2b, atf6, birc2, bmp4, casp3b, casp9, cat, cdc42, chmp4bb, ctnnbl1, dad1, E2F1, egr1, eif2s1b, fgfr1b, foxa1, gsk3b, hdac1, hdac3, hdac6, hmox1a, hsf1, hsp90b1, hspa9, id1, jun, mcl1a, mre11a, mt2, myb, myca, ncoa1, nkx2.7, nr1h4, pak2a, park7, pdx1, pparab, ppp2r1b, psmc1b, psmd10, psme3, rarga, rps3a, rps6kb1b, rtn4a, sap18, sirt2, slc25a5, smo, src, tcf7l2, tgfb2, tgfb3, thraa, uba52, vegfaa, xbp1","N/A CELL INJURY/DEATH"
"CTOME SIGNALING BY EGFR","4","1.0133349261588","0.153140724074186","50","cdc42, nras, src, uba52","ACTIVATION EGFR"
"INCREASED SUSCEPTIBILITY TO FRACTURES","7","1.0352906255048","0.0567918503512584","20","fgfr1b, gatm, hnrnpa1b, kdelr2b, nhp2, nras, plod3","INCREASED DISEASE SUSCEPTIBILITY"
"GO:0042116","5","1.04245021125173","0.0690542966562014","33.33","jun, ldlra, mmp13a, nr1h3, roraa","INCREASED ACTIVATION AND RECRUITMENT OF HEPATIC MACROPHAGES KUPFFER CELLS"
"GO:0000003","48","1.05110423286067","0.0185555930937678","23.65","adra2c, arrb2b, avpr1a, birc2, bmp4, casp3b, ccnb1, crhr1, ctsla, E2F1, egr1, eif2b2, eif2b4, eif2s2, foxa1, gamt, h2afx, hsf1, inhbaa, krt8, lfng, mre11a, msh6, ncoa1, ndc1, nup107, oprl1, paqr7b, park7, pdgfra, ppat, ppp2ca, ppp2r1b, psmd13, ptgs2b, rarga, rdh10a, rnf2, rpa1, rps6kb1b, rxraa, sirt2, src, tgfb2, tgfb3, thraa, thrb, zw10","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"GO:0044703","28","1.05844410681019","0.0298240680003867","24.14","adra2c, avpr1a, birc2, bmp4, ccnb1, crhr1, ctsla, E2F1, eif2s2, gamt, h2afx, hsf1, inhbaa, ncoa1, ndc1, paqr7b, park7, ppat, ppp2r1b, ptgs2b, rnf2, rps6kb1b, rxraa, sirt2, src, tgfb3, thraa, thrb","N/A REPRODUCTIVE FAILURE"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","19","1.06296100168883","0.0531370448121946","18.45","ahr1b, bmp4, cyb5a, eif2b2, eif2b4, fgfr1b, foxa2, hnf1ba, mre11a, nras, nup107, park7, pmm2, polr1c, prpf31, prpf4, rras, smo, sox19b","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"ELECTRON TRANSPORT CHAIN","16","1.08260587161637","0.0679268388814835","23.53","adh5, ccnb1, cox5aa, COX5B_2of3, cox6b1, cox7c, cyb5a, cyc1, ndufa12, ndufa5, ndufa8, ndufs2, ndufs8a, p4ha2, park7, sdhb","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"NCRNAS INVOLVED IN WNT SIGNALING IN HEPATOCELLULAR CARCINOMA","8","1.10727066379255","0.0389058561556029","16.67","csnk1e, CSNK2A1, elavl1, fzd2, gsk3b, jun, myca, tcf7l2","INCREASE HERITABLE MUTATIONS IN OFFSPRING"
"REGULATION OF SPINDLE CHECKPOINT","2","1.13000253162218","0.162017790192126","66.67","ccnb1, tprb","UPREGULATED SPINDLE ASSEMBLY CHECKPOINT PROTEIN MAD2-OOCYTE"
"ABNORMAL LUNG MORPHOLOGY","25","1.13179969804714","0.0377435130847348","19.53","agrn, ak2, birc2, cdc42, farsb, fgfr1b, gatm, lfng, lipf, mthfd1b, nfkb2, nhp2, nras, nup107, orc6, pax6b, pdgfra, pmm2, rac1a, rarga, rras, smo, stxbp2, tgfb2, tgfb3","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"GO:0030163","41","1.13828110472192","0.0172757283469104","26.8","ap2b1, ap2m1a, arrb2b, birc2, ccnb1, csnk1e, ctsla, cul1a, gsk3b, hdac6, hsp90b1, ldlra, nploc4, nsfl1c, park7, psma5, psmb3, psmc1a, psmc2, psmc4, psmc6, psmd1, psmd10, psmd13, psmd14, psmd5, psmd6, psme3, rchy1, rnf185, rock1, sf3b3, sirt2, tceb1b, timp2a, uba52, ube2kb, ube4b, usp14, xbp1, zgc-86598","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"GO:0007612","5","1.14862348685931","0.0834205527388518","20.83","drd2b, jun, oprl1, ptgs2b, vdac3","IMPAIRMENT LEARNING AND MEMORY"
"GO:0048856","3","1.1676239110733","0.15887795295055","25","nr2f5, nr2f6a, rxraa","ALTERED NEUROANATOMY"
"GO:0019098","4","1.16782386020134","0.111085395623147","44.44","avpr1a, ncoa1, thraa, thrb","ALTERED REPRODUCTIVE BEHAVIOUR; REDUCED BROOD CARE"
"APOPTOSIS","6","1.17178712748556","0.0533623599707466","10.71","birc2, casp3b, casp9, jun, mcl1a, myca","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"LIVER X RECEPTOR PATHWAY","3","1.18505056108359","0.160072570653321","25","cyp3c1, nr1h3, rxraa","ACTIVATION LXR; ACTIVATION LXR ALPHA"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","49","1.19412998058105","0.0136292005146246","12.13","actn1, ak2, alg8, atp6ap1b, birc2, cat, cdc42, cpox, cyb5a, farsb, fh, flt1, hmox1a, hspa9, ivd, lipf, map2k2a, msh6, mthfd1b, myca, ndufa12, ndufs2, ndufs8a, nfkb2, nhp2, nr1h4, nras, pccb, pdgfra, pdx1, plat, plod3, pmm2, pomp, rbm8a, rnaseh2b, rpl18, rps19, rps29, rras, sdhb, sec61a1, smo, src, stxbp2, tbxas1, tgfb2, tgfb3, thraa","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"REGULATION OF ATPASE ACTIVITY","3","1.20440768917175","0.14621541696512","18.75","atp1b3b, gtf2h4, msh6","INHIBITION CA++ ATPASE"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","30","1.20451727459785","0.0289186506985182","20.41","agrn, ak2, birc2, cat, cdc42, farsb, fgfr1b, fus, gatm, hnrnpa1b, lfng, lipf, msh6, mthfd1b, nfkb2, nhp2, nras, nup107, orc6, pax6b, pdgfra, pmm2, polr1c, rac1a, rarga, rras, smo, stxbp2, tgfb2, tgfb3","INCREASED RESPIRATORY DISTRESS/ARREST"
"GO:0003158","7","1.21823311773216","0.0563117737838457","29.17","bmp4, f11r.1, gstm, id1, plod3, rap1aa, rock1","IMPAIRMENT ENDOTHELIAL NETWORK"
"CTOME CELLULAR RESPONSE TO HYPOXIA","16","1.22897021327896","0.0256800982272052","37.21","psma5, psmb3, psmc1b, psmc2, psmc4, psmc6, psmd1, psmd10, psmd13, psmd14, psmd5, psmd6, psme3, tceb1b, uba52, vegfaa","N/A HYPOXIA"
"JNK CASCADE","6","1.23061052159075","0.0857977536761536","27.27","cdc42, hacd3, hdac3, mmp13a, uba52, ube2nb","ACTIVATION JNK"
"GO:0051899","3","1.23610914396076","0.152651457518809","14.29","jun, park7, src","OCCURRENCE A PAROXYSMAL DEPOLARIZING SHIFT; PROLONGED DEPOLARIZATION OF NEURONAL MEMBRANE"
"POSITIVE REGULATION OF GENE EXPRESSION","38","1.24911115160232","0.0230165453436626","20.99","actb1, arrb2b, bmp4, dyrk1ab, E2F1, egr1, eif3d, elavl1, fus, gsk3b, hdac1, hmox1a, id1, map2k2a, mmp13a, mre11a, mt2, myb, myca, nfkb2, park7, pax6b, polr1c, polr1e, polr3f, polr3k, ptgs2b, rock1, roraa, rps6kb1b, rps9, smo, sox19b, src, srsf5b, vegfaa, xbp1, znrd1","ALTERED GENE EXPRESSION"
"GO:0030154","24","1.2769674373129","0.0207336933822534","36.92","agrn, cpsf5, foxa1, foxa2, hs6st2, kif1bp, lfng, nkx2.7, nr1h3, nr1h4, nr2f5, nr2f6a, onecut1, otpb, paqr7b, pparaa, pparab, rarga, rxraa, sox19b, src, thraa, thrb, vegfaa","DIFFERENTIATION OF MYOFIBROBLAST"
"MATING BEHAVIOR","5","1.28873330628904","0.0793051488067031","55.56","avpr1a, hdac1, ncoa1, thraa, thrb","REDUCED ABILITY TO ATTRACT SPAWNING MATES"
"REPRODUCTIVE BEHAVIOR","5","1.28873330628904","0.0793051488067031","50","avpr1a, hdac1, ncoa1, thraa, thrb","REDUCED SPAWNING BEHAVIOR"
"GO:0006635","4","1.28963350078786","0.0633186357590321","20","bdh2, cpt1aa, ivd, pparab","DECREASED PEROXISOMAL FATTY ACID BETA OXIDATION OF FATTY ACIDS; DECREASED MITOCHONDRIAL FATTY ACID BETA OXIDATION; DECREASED MITOCHONDRIAL FATTY ACID BETA-OXIDATION; INHIBITION MITOCHONDRIAL FATTY ACID BETA-OXIDATION"
"GO:0007249","12","1.30968120162474","0.0268604941670015","27.91","birc2, hacd3, hdac1, hmox1a, MAP3K14_2of2, nfkb2, nr1h4, ppm1bb, rock1, roraa, uba52, wls","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"GO:0009611","27","1.31431120691117","0.0134695425990975","24.11","actb1, adra2c, arrb2b, casp3b, ccnb1, cdc42, drd2b, f11r.1, foxa2, hdac1, hmox1a, ilk, jun, map2k2a, pax6b, pdgfra, pdx1, plat, pparab, rab5ab, rac1a, rps6kb1b, src, tgfb2, tgfb3, usf1, xbp1","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GO:0007059","12","1.31516947998182","0.0333306570516104","27.27","ccnb1, cdc42, mre11a, ndc1, ppp2r1b, riok2, seh1l, sirt2, slc25a5, tprb, zgc-86598, zw10","INCREASED CHROMOSOME MISSEGGREGATION"
"GO:0019882","17","1.3320963888321","0.0233519286522066","28.81","ap2b1, ap2m1a, ctsla, psma5, psmb3, psmc1a, psmc2, psmc4, psmc6, psmd1, psmd10, psmd13, psmd14, psmd5, psmd6, psme3, sec13","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"CTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP","4","1.33957120549805","0.101988701262966","33.33","ncoa1, ncoa2, pparab, rxraa","UP REGULATION SREBF2"
"GO:0001816","31","1.34686140620782","0.0256668898702107","25.83","agtr2, arrb2b, birc2, drd2b, egr1, EPHA2_2of2, f11r.1, fgfr1b, hmox1a, hsf1, inhbaa, lipf, mmp13a, mre11a, myb, nfkb2, nploc4, nr1h4, park7, polr1c, polr3f, polr3k, ppm1bb, ptgs2b, rac1a, roraa, seh1l, src, tgfb2, tgfb3, xbp1","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"GO:1903009","13","1.3725458791263","0.0326295841643697","38.24","pomp, psma5, psmb3, psmc1a, psmc1b, psmc2, psmc4, psmc6, psmd1, psmd13, psmd14, psmd6, psme3","DECREASE GTPCH-1"
"ARYL HYDROCARBON RECEPTOR PATHWAY","4","1.38635045426746","0.0964192541414214","8.33","ahr1b, jun, ncoa1, src","UP REGULATION CYP1A1; ACTIVATION AHR"
"CONSTITUTIVE ANDROSTANE RECEPTOR PATHWAY","4","1.39236986104774","0.10411100350366","13.33","cyp3c1, ncoa1, ncoa2, rxraa","SUPPRESSION CONSTITUTIVE ANDROSTANE RECEPTOR NR1L3; ACTIVATION CONSTITUTIVE ANDROSTANE RECEPTOR"
"SIGNALING OF HEPATOCYTE GROWTH FACTOR RECEPTOR","4","1.40306151118589","0.0972496855432862","11.76","jun, map2k2a, rap1aa, src","OCCURRENCE CYTOPLASMIC VACUOLIZATION HEPATOCYTE; OCCURRENCE BALLOONING DEGENERATION HEPATOCYTE"
"CTOME REGULATED NECROSIS","4","1.41999289156261","0.0652403627196412","19.05","birc2, casp3b, chmp4bb, uba52","INCREASE NECROSIS TERMINAL BRONCHIOLAR CELLS"
"PROLONGED NEONATAL JAUNDICE","4","1.42572163714183","0.102522707810649","66.67","atp6ap1b, cpox, rnaseh2b, trhra","PROLONGED ESTRUS"
"GO:0022414","7","1.44153664775925","0.0393441503605005","19.44","ccnb1, h2afx, mre11a, msh6, paqr7b, park7, rpa1","INCREASED REPRODUCTIVE SUCCESS"
"GO:0006281","18","1.442137541737","0.01688494725275","21.18","cdc5l, csnk1e, fh, fus, gtf2h4, h2afx, hsf1, mre11a, msh6, nploc4, park7, polr2j, psmd14, rbm17, rchy1, rpa1, rpa3, uba52","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"GO:0042060","21","1.46571950424348","0.016058418290715","23.86","actb1, adra2c, arrb2b, casp3b, ccnb1, cdc42, f11r.1, foxa2, hdac1, hmox1a, ilk, pdgfra, plat, pparab, rab5ab, rac1a, src, tgfb2, tgfb3, usf1, xbp1","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0001775","45","1.46684887221357","0.00753607167023483","22.96","actb1, adra2c, ahr1b, arrb2b, bmp4, casp3b, cat, cdc42, cdk6, egr1, f11r.1, hmox1a, ilk, inhbaa, jun, krt8, ldlra, lfng, mmp13a, msh6, myb, nfkb2, nr1h3, nras, onecut1, pak2a, pdgfra, psma5, psmc2, psmd1, psmd13, psmd14, psmd6, ptgesl, ptprb, rab5c, rac1a, rap1aa, rock1, roraa, smo, src, stxbp2, timp2a, xbp1","ACTIVATION DENDRITIC CELLS"
"G VEGF SIGNALING PATHWAY","8","1.47135012882934","0.0547857882943959","38.1","casp9, cdc42, map2k2a, nras, ptgs2b, rac1a, src, vegfaa","REDUCED PRODUCTION VEGF"
"NRF2 PATHWAY","6","1.47634540207914","0.0535627284956195","15","egr1, EPHA2_2of2, hmox1a, pgd, rxraa, tgfb2","ACTIVATION NRF2"
"GO:0030520","3","1.48076907240379","0.113451563125454","37.5","foxa1, src, taf7","ACTIVATION ESTROGEN RECEPTOR ALPHA"
"GO:0050805","6","1.50689418804664","0.0511725555463113","35.29","drd2b, gria1b, npy2r, pcdh17, ptgs2b, rap1aa","INCREASED NEURONAL SYNAPTIC INHIBITION"
"GO:0007568","17","1.52993471977415","0.0173481766222602","19.77","casp9, cat, cdk6, ctsla, eif2s1b, h2afx, ilk, jun, msh6, nfkb2, npy2r, pdx1, ptgs2b, rpn2, rps6kb1b, tgfb3, timp2a","ACCELERATED AGING"
"GO:0072358","25","1.53778490828484","0.0126314553116221","22.52","ahr1b, ap2b1, bmp4, cdc42, ednraa, egr1, EPHA2_2of2, fgfr1b, flt1, hmox1a, id1, jun, ldlra, pax6b, pdgfra, ptgs2b, ptprb, rap1aa, rock1, roraa, rras, smo, tcf7l2, tgfb2, xbp1","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"GO:0001963","4","1.54486151667839","0.0906533481385365","33.33","arrb2b, drd2b, park7, ptgs2b","INCREASE DOPAMINERGIC ACTIVITY; DECREASED DOPAMINERGIC ACTIVITY"
"GO:0007051","5","1.54937687553386","0.0427341387893494","18.52","ccnb1, hdac3, ppp2r1b, rae1, tprb","DISORGANIZATION SPINDLE"
"DNA DAMAGE RESPONSE","8","1.55423678142471","0.0269585516486593","13.79","casp3b, casp9, ccnb1, cdk6, E2F1, h2afx, mre11a, myca","INCREASED DNA DAMAGE-REPAIR"
"GO:1904019","7","1.5978311725954","0.0469059687803505","31.82","arrb2b, E2F1, eif2s1b, hmox1a, krt8, pdx1, tcf7l2","DECREASE APOPTOSIS OF CILIATED EPITHELIAL CELLS"
"GO:0006898","10","1.59826829346623","0.0255005096239726","26.32","ap2b1, ap2m1a, arrb2b, colec11, drd2b, gria1b, hsp90b1, ldlra, rab5ab, rac1a","REDUCTION VITELLOGENIN ACCUMULATION INTO OOCYTES AND OOCYTE GROWTH/DEVELOPMENT; INCREASED LDL UPTAKE"
"GO:0001935","8","1.6146991225542","0.0331764266812034","22.22","bmp4, EPHA2_2of2, fgfr1b, flt1, hmox1a, jun, nras, xbp1","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"GO:0004882","6","1.61524445400695","0.0528958401896112","17.14","hdac1, jun, ncoa1, ncoa2, rchy1, src","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"GO:0016055","6","1.61646559697131","0.0459327238661913","26.09","ap2m1a, fzd2, hdac1, tcf7l1b, tcf7l2, wls","ALTERATION WNT PATHWAY"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","4","1.62753659471642","0.0700564169165426","28.57","cyb5a, nup107, smo, sox19b","INCREASED CIRCULATING ESTROGEN LEVELS"
"GO:0006839","12","1.63829227784248","0.0267701329398244","26.09","atp5f1, atp5g3a, atp5g3b, COX5B_2of3, cpt1aa, cyc1, E2F1, gsk3b, kif1bp, nmt1a, sae1, slc25a5","REDUCTION CHOLESTEROL TRANSPORT IN MITOCHONDRIA"
"ABNORMAL CIRCULATING CHOLESTEROL CONCENTRATION","4","1.64212617798488","0.0643818011900547","36.36","ldlra, lipf, nup107, pmm2","DECREASED CHOLESTEROL; PERTURBATION OF CHOLESTEROL"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","7","1.65302093848344","0.0419694277509413","6.48","E2F1, egr1, jun, myca, rap1aa, rps6kb1b, src","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"ABNORMALITY OF THE PITUITARY GLAND","12","1.65625337594159","0.024630386091394","25","bmp4, cyb5a, dyrk1ab, fgfr1b, foxa2, msh6, nfkb2, nup107, pmm2, smo, sox19b, thrb","INCREASED ADENOMAS PITUITARY"
"BREAST CANCER PATHWAY","15","1.67830487401647","0.0147866181922942","13.16","cdk6, CSNK2A1, E2F1, fgfr1b, fzd2, gsk3b, jun, map2k2a, mre11a, myca, ncoa1, nfkb2, nras, rps6kb1b, tcf7l2","N/A BREAST CANCER"
"PARALYSIS","6","1.6875716084864","0.0438537398608745","26.09","cpox, fgfr1b, fh, fus, hnrnpa1b, sdhb","INDUCTION SOMATIC MUSCLE PARALYSIS; INDUCTION PHARYNGEAL MUSCLE PARALYSIS"
"DECREASED FERTILITY","5","1.69557814287791","0.0492432781401725","6.58","cyb5a, fgfr1b, foxa2, nup107, sox19b","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"G TGF BETA SIGNALING PATHWAY","8","1.70362950733018","0.0305015964321325","11.76","bmp4, id1, myca, ppp2r1b, rock1, rps6kb1b, tgfb2, tgfb3","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"SMOOTH MUSCLE CELL PROLIFERATION","7","1.70451278543047","0.0424037280648107","26.92","bmp4, hmox1a, jun, myb, rps6kb1b, tcf7l2, tgfb3","HYPERTROPHY/HYPERPLASIA SMOOTH MUSCLE"
"ABNORMALITY OF THE OVARY","14","1.74638830379717","0.0171854117380971","24.56","bmp4, cyb5a, eif2b2, eif2b4, fgfr1b, flt1, mre11a, msh6, myca, nup107, pax6b, pmm2, sdhb, sox19b","REDUCED PROSTAGLANDINS OVARY"
"ENDOMETRIAL CANCER","8","1.76049200801795","0.0187397887363956","11.76","casp9, fgfr1b, gsk3b, ilk, map2k2a, myca, nras, tcf7l2","INCREASE ENDOMETRIAL ADENOCARCINOMAS"
"RESPONSE TO ESTRADIOL","5","1.78276809749801","0.0528065727346484","16.67","casp3b, cat, foxa1, hsf1, ncoa1","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"TRIGLYCERIDE METABOLIC PROCESS","5","1.83424604777216","0.048493770203403","31.25","cat, cpt1aa, ldlra, lipf, nr1h3","ACCUMULATION TRIGLYCERIDE"
"INCREASED LEVEL OF HIPPURIC ACID IN URINE","2","1.83983227568057","0.0562359709160302","66.67","bckdha, pccb","INCREASED BLOOD URIC ACID CONCENTRATION"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","2","1.8620255850338","0.0180418112563998","15.38","fgfr1b, nras","INCREASED IGF-1 MOUSE"
"ABNORMAL OVARIAN MORPHOLOGY","8","1.86871564530984","0.0244498913327832","21.62","cyb5a, fgfr1b, flt1, nup107, pax6b, pmm2, sdhb, sox19b","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"GO:0042698","10","1.90170295058096","0.0181750476888937","45.45","arrb2b, casp3b, egr1, inhbaa, ncoa1, oprl1, pdgfra, src, tgfb2, tgfb3","IRREGULARITIES OVARIAN CYCLE"
"ABNORMAL CORNEAL EPITHELIUM MORPHOLOGY","2","1.95242163028382","0.0323120881120589","15.38","kif1bp, pax6b","INCREASED ACCUMULATION OF ALPHA2U MICROGLOBULIN PROXIMAL TUBULAR EPITHELIUM"
"GO:0006816","2","2.0573653033309","0.0236004877061368","18.18","atp2a1, slc8a1a","DECREASED CALCIUM INFLUX; REDUCTION CA AND HCO3 TRANSPORT TO SHELL GLAND; OPENING OF CALCIUM CHANNEL CALCIUM INFLUX"
"CTOME VEGFR2 MEDIATED CELL PROLIFERATION","3","2.06199965837795","0.0205393996103063","50","nras, src, vegfaa","INHIBITION VEGFR2"
"HEPATOCELLULAR CARCINOMA","2","2.06640315704692","0.0137204419463175","15.38","cpox, msh6","FORMATION HEPATOCELLULAR AND BILE DUCT TUMORS; INCREASE ADENOMAS/CARCINOMAS HEPATOCELLULAR; TUMORIGENESIS HEPATOCELLULAR CARCINOMA"
"SOMATIC MUTATION","8","2.07065458210388","0.00445295459895828","9.52","fgfr1b, msh6, myca, nras, pax6b, pdgfra, smo, src","INCREASED INDUCED MUTATIONS IN CRITICAL GENES; INCREASE MUTATIONS; INCREASE MUTATIONS IN CRITICAL GENES"
"CTOME METABOLISM OF PORPHYRINS","2","2.08001892415963","0.0117036110952114","66.67","cpox, hmox1a","ACCUMULATION HIGHLY CARBOXYLATED PORPHYRINS"
"NEOPLASM OF THE SKIN","6","2.08586379972125","0.00818138605778659","18.18","fgfr1b, fh, msh6, nras, sdhb, smo","SENSITISATION SKIN"
"IMMUNOLOGIC HYPERSENSITIVITY","5","2.09440112048228","0.00563844830335977","21.74","fgfr1b, nfkb2, ptger2a, ptger2b, rbm8a","INCREASE ALLERGIC RESPIRATORY HYPERSENSITIVITY RESPONSE"
"GO:0048469","7","2.09825614080437","0.0091686529892206","29.17","agrn, ccnb1, fgfr1b, foxa1, ppp2r1b, sirt2, xbp1","INCREASED OOCYTE MATURATION"
"GO:0004620","2","2.10108831303943","0.014798632221245","40","ednraa, hmox1a","INHIBITION PHOSPHOLIPASE A"
"REGULATION OF SODIUM ION TRANSPORT","2","2.11432054157434","0.0319863624728505","16.67","atp1b3b, slc8a1a","INHIBITION SODIUM CHANNEL; MODULATION SODIUM CHANNEL"
"GO:0030331","4","2.11638530064008","0.00546852175830734","44.44","fus, ncoa1, src, taf10","INCREASED ER BINDING TO DNA CLASSICAL PATHWAY; INCREASED ER BINDING TO TF TO DNA NON-CLASSICAL PATHWAY"
"BLADDER CANCER","6","2.12869182478276","0.00727119592349398","14.29","E2F1, map2k2a, myca, nras, src, vegfaa","INCREASE CANCER"
"TUBE FEEDING","4","2.13118679500128","0.0101765065572024","23.53","dyrk1ab, fgfr1b, fus, ppp2r1b","INHIBITION FEEDING"
"ABNORMAL RENAL TUBULE MORPHOLOGY","5","2.16464339781223","0.00270798776567438","55.56","alg8, ndufs2, nup107, nup133, pmm2","OCCURRENCE CYSTIC DILATATION RENAL TUBULE; OCCURRENCE CYTOPLASMIC VACUOLIZATION RENAL TUBULE"
"ABNORMALITY OF THE ENDOMETRIUM","2","2.16585074444816","0.0281549436311176","18.18","msh6, sdhb","INCREASED HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASE HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASED ADENOSQUAMOUS CARCINOMAS OF ENDOMETRIUM"
"INCREASED CIRCULATING PROLACTIN CONCENTRATION","2","2.17022213356726","0.0125312869421838","40","pmm2, smo","INCREASED PROLACTIN SECRETION; INCREASED PROLACTIN EXPOSURE"
"LOW DENSITY LIPOPROTEIN RECEPTOR PARTICLE METABOLIC PROCESS","2","2.17972742087687","0.0234998879806019","33.33","ap2b1, ap2m1a","UP REGULATION LDLR LOW DENSITY LIPOPROTEIN RECEPTOR"
"GO:0010463","3","2.18579945646558","0.012972571441728","25","bmp4, fgfr1b, smo","INCREASED PROLIFERATION OF MESENCHYMAL CELLS"
"ABNORMAL HYPOTHALAMUS PHYSIOLOGY","3","2.19303686090688","0.0135310236407281","33.33","fgfr1b, smo, trh","REDUCED PROSTAGLANDIN E2 CONCENTRATION HYPOTHALAMUS; DECREASE E2 BLOOD CONCENTRATIONS AT HYPOTHALAMUS"
"GO:0006120","6","2.19590721067008","0.00689769284615525","22.22","ndufa12, ndufa5, ndufa8, ndufs2, ndufs8a, park7","BINDING OF INHIBITOR NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"GO:0036475","2","2.21558860749177","0.0209631496293782","40","mcl1a, park7","N/A NEURONAL DYSFUNCTION"
"YOUNG ADULT ONSET","2","2.2238441579462","0.00882869331381015","66.67","actb1, cpox","REDUCED YOUNG OF YEAR SURVIVAL"
"GPCRS CLASS C METABOTROPIC GLUTAMATE PHEROMONE","2","2.2421216442307","0.000464135567569347","66.67","gabbr1b, gabbr2","REDUCED PHEROMONE RELEASE"
"ABNORMAL SOCIAL BEHAVIOR","6","2.24349124604765","0.00311992786882689","23.08","adsl, gabbr2, gria3b, ndufs2, ndufs8a, park7","ABNORMAL FORAGING ACTIVITY AND BEHAVIOR"
"TISSUE ISCHEMIA","3","2.24693106354181","0.00856496704897479","20","actb1, tgfb2, tgfb3","OCCURRENCE RENAL ISCHEMIA"
"GO:0004970","2","2.25082526928314","0.0220593179988112","33.33","gria1b, gria3b","BINDING OF AGONIST IONOTROPIC GLUTAMATE RECEPTORS"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","3","2.25113909749318","0.00847131218654718","16.67","rpl18, rps19, rps29","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","3","2.25113909749318","0.00847131218654718","15","rpl18, rps19, rps29","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"VENTRICULAR ARRHYTHMIA","2","2.2714440486476","0.0113354540610182","28.57","ndufs2, tgfb3","OCCURRENCE CARDIAC ARRHYTHMIA"
"ABNORMAL PROLACTIN LEVEL","2","2.27357243161665","0.00175552705044972","25","foxa2, smo","DECREASED PROLACTIN"
"GO:0032964","5","2.28627231789414","0.00253571330566831","50","arrb2b, bmp4, myb, rap1aa, tgfb3","ACCUMULATION COLLAGEN; EXPRESSION OF COLLAGEN"
"GO:0001909","2","2.29079527095384","0.0134466700936452","33.33","arrb2b, stxbp2","INCREASE CYTOTOXICITY"
"HYPERTENSION ASSOCIATED WITH PHEOCHROMOCYTOMA","2","2.30596883654635","0.00890402578746314","28.57","fh, sdhb","INCREASE HYPERTENSION"
"PSYCHOGENIC NON EPILEPTIC SEIZURE","4","2.30695689486287","0.00353836069243023","30.77","fh, gabbr2, park7, sdhb","OCCURRENCE EPILEPTIC SEIZURE"
"GO:0005125","4","2.31756516509976","0.00763613613024509","16","bmp4, inhbaa, tgfb2, tgfb3","ACTIVATION INFLAMMATORY CYTOKINES CHEMOKINES CYTOPROTECTIVE GENE PATHWAYS"
"GO:0009653","2","2.38347692586906","0.0127416874702668","40","foxa1, foxa2","INCREASED DEVELOPMENTAL DEFECTS"
"GLUTATHIONE METABOLIC PROCESS","2","2.38464765606413","0.00161837297699596","20","park7, ptgesl","GLUTATHIONE SYNTHESIS; GLUTATHIONE HOMEOSTASIS"
"REGULATION OF PH","2","2.44171275771845","0.00457335511938528","14.29","atp6ap1b, avpr1a","DECREASE INTRACELLULAR PH"
"GO:0030728","2","2.48126678058519","0.000827951791046159","40","inhbaa, ptgs2b","DECREASE OVULATION"
